Research Development

Staff Publications

 Small purple icon of a book with a magnifying glass on top  Staff Publications

Find out what your colleagues have been writing. This section features articles published by staff working for St Helens and Knowsley Teaching Hospitals and Halton, Knowsley and St Helens community staff.

Had something published and it's not included here? Let us know by completing this form.

Resources pertaining to writing for a publication and how to get published can be found by clicking here.

 

All publications by 'Nicholson T'



Mersey and West Lancashire Teaching Hospitals Staff

No results for this category.

St Helens and Knowsley Hospital Staff - Publications pre April 2024

Ibrutinib as first line therapy for mantle cell lymphoma: A multicentre, real-world UK study

Abstract During the Covid-19 pandemic, ibrutinib +/- rituximab was approved in England for initial treatment of mantle cell lymphoma (MCL) instead of immunochemotherapy. As limited data are available in this setting, we conducted an observational cohort study evaluating safety and efficacy. Adults receiving ibrutinib +/- rituximab for untreated MCL were..

Published: 21/12/2023
Authors: Nicholson T

Read More

P1141: Ibrutinib and rituximab as first line therapy for mantle cell lymphoma: a multicentre, real-world UK study

Background Ibrutinib (IBR) is an oral covalent Bruton tyrosine kinase inhibitor (BTKi), licensed for treatment of relapsed or refractory mantle cell lymphoma (MCL). Under NHS interim Covid-19 agreements in England, IBR with or without rituximab (R) was approved for the frontline treatment for MCL patients (pts) as a safer alternative..

Published: 14/06/2022
Authors: Nicholson T

Read More

A retrospective observational study to evaluate the clinical outcomes and routine management of patients with chronic lymphocytic leukaemia...

Summary Idelalisib (IDL) is an oral first-in-class phosphatidylinositol 3-kinase delta (PI3Kδ) inhibitor approved for chronic lymphocytic leukaemia (CLL) alongside rituximab (R) since 2014. However, little data exist on routine practice. The RETRO-idel was a protocol-led, retrospective study of 110 patients [n = 27 front-line (1L)] who received IDL-R. The primary end-point was clinical..

Published: 08/07/2021
Authors: Nicholson T

Read More

Second primary malignancies in patients receiving treatment with ruxolitinib for myelofibrosis – a regional experience

Patients with myeloproliferative neoplasms (MPN) are at an increased risk of second primary malignancies (SPM) compared with matched‐controls and the general population. The Surveillance, Epidemiology and End Results (SEER) database (US cancer registries) reported that patients with primary myelofibrosis (PMF) had an incidence of SPM of 5·3% after a median..

Published: 01/05/2020
Authors: Nicholson T

Read More

A unique presentation of destructive shoulder arthropathy in the chronic phase of chronic myeloid leukaemia

​We present a previously unreported case of rapidly progressing, destructive shoulder arthropathy as an initial presentation of chronic phase chronic myeloid leukaemia. This patient initially presented to clinic for consideration of an arthroplasty for symptom relief; however, her loss to follow-up yielded a rapid progression of her symptoms. Bone marrow..

Published: 26/06/2019
Authors: Connolly S, Howard J, MacKenzie B, Nicholson T,

Read More

Haematology Speciality Trainees Driving NIHR Clinical Research

Abstract In 2016, the NIHR Haematology National Speciality Group founded a pilot programme to develop the clinical research skills of Haematology trainees within Non‐Malignant Haematology (NMH). This unique initiative has since been rolled out successfully throughout CRNs nationwide and equips Haematology trainees with the skills to become future leaders in..

Published: 05/06/2018
Authors: Loizou E, Nicholson T

Read More

Genotype-guided dosing of warfarin

​ BACKGROUND The level of anticoagulation in response to a fixed-dose regimen of warfarin is difficult to predict during the initiation of therapy. We prospectively compared the effect of genotype-guided dosing with that of standard dosing on anticoagulation control in patients starting warfarin therapy. METHODS We conducted a multicenter, randomized, controlled..

Published: 19/07/2016
Authors: Nicholson T

Read More

St Helens Community Staff

No results for this category.

Knowsley Community Staff

No results for this category.

Halton Community Staff

No results for this category.

North West Boroughs Community Health Staff

No results for this category.